Silymarin is kind of a flavonoid lignans compounds extracted from the seed coats of the medicinal compositae Silybum marianum, light yellow powder, bitter in taste. It is oluble in Acetone, Ethyl Acetate, Ethanol and Methanol, Hardly soluble in chloroform, insoluble in water. The main ingredient of Milk Thistle extract are : Silymarin, Silybin, Isosilybin, Silydianin, Silychristin, etc

Product specification:

Products' Name	Specification
Silymarin Extracted By Acetone	UV80% Silybin + Isosilybin 30%
	HPLC 50%
	HPLC 53%
	HPLC 55%
	HPLC 60%
	UV 70%
Silymarin Extracted By Ethyl Acetate	UV80% Silybin + Isosilybin 30%
	HPLC 50%
	HPLC 55%
	HPLC 60%
Silymarin Extracted Ethanol	UV80% Silybin + Isosilybin 30%
	HPLC 50%
	HPLC 55%
	HPLC 60%
Granular/ Micro Powder Silymarin	Accoroding To Customer' Requirements
Silybin	HPLC 60% ~99%
Water Soluble Silymarin	UV 20%
	UV 40%
	UV 45%
Water Soluble Silybin	HPLC 75%, UV 96%

 

Function of Milk Thistle Extract
1.Milk Thistle Extract protects liver cell membrane and improve the liver function; 
2.Milk Thistle Extract is used for treating hepatitis;
3. Milk Thistle Extract is used to detoxify, reduce the blood fat. 
4.Milk Thistle Extract can protect the brain and remove the free radical of body; 
5.Milk Thistle Extract has benefit of regenerating liver cell; 
6.Milk Thistle Extract has anti-atherosclerotic effect
7.Milk Thistle Extract is strongly antioxidant, can remove the body of free radicals, delay senescence.
8.Milk Thistle Extract is widely applied in pharmaceuticals to treat and prevent liver related disease, hepatitis, fatty liver, Cirrhosis and cardiovascular disease

Application of Milk Thistle Extract
Milk Thistle Extract is widely applied in pharmaceuticals to treat and prevent liver related disease, hepatitis, fatty liver, Cirrhosis and cardiovascular disease.
Some German companies have already made it into pills, such as Heplant, Silimarit, Silidanin, Hepabene, Heliplant and so on.

For more product information pls contact email sales09@staherb.cn

References:

 

1. 1.

   Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States. The Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;178:38–45.

2. 2.

   Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.

3. 3.

   Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon. 2011;11:173–7.

4. 4.

   Pasumarthy L, Srour J. Nonalcoholic steatohepatitis: a review of the literature and updates in management. South Med J. 2010;103:547–50.

5. 5.

   Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. AM J Gastroenterol. 2003;98:960–7.

6. 6.

   Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.

7. 7.

   Burczynski FJ, Wang G, Nguyen D, Chen Y, Smith HJ, Gong Y. Silymarin and hepatoprotection. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37:6–10.

8. 8.

   Li CC, Hsiang CY, Wu SL, Ho TY. Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-κB bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol. 2012;50:1568–75.

9. 9.

   George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003;39:756–64.

10. 10.

    Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–23.

11. 11.

    Kwon DY, Ahn CW, Choi YJ, Kim YC. Induction of hepatic glutathione synthesis via alterations in sulfur amino acid metabolism in mice treated with silymarin acutely. FASEB J. 2013;27(805):1.

12. 12.

    Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23:749–54.

13. 13.

    Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003;37:336–9.

14. 14.

    Kim M, Yang S-G, Kim JM, Lee J-W, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. Int J Mol Med. 2012;30:473–9.

15. 15.

    Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL. Rationale, challenges, and participants in a phase II trial of a botanical product for chronic hepatitis C. Clin Trials. 2012;9:102–12.

16. 16.

    Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol. 1982;17:517–21.

17. 17.

    Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105–13.

18. 18.

    Feher J, Deak G, Muzes G, et al. Hepatoprotective activity of silymarin (Legalon) therapy in patients with chronic liver disease. Orv Hetil. 1989;130:2723–7.

19. 19.

    Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orv Hetil. 1990;22;131:863–6. Hungarian.

20. 20.

    Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871–9.

21. 21.

    Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–63.

22. 22.

    Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sánchez-de la Cuesta F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther. 2002;40:2–8.

23. 23.

    Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung. 1992;80:363–7.

24. 24.

    Buturova LI, Tsybizova TA, Kalinin AV. Use of Legalon in non-alcoholic fatty liver disease [in Russian]. Eksp Klin Gastroenterol. 2010;5:69–75.

25. 25.

    Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141–52.

26. 26.

    Kleiner DE, Brunt EM, Van Natta M, Nonalcoholic Steatohepatitis Clinical Research Network, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

27. 27.

    Klein T, Fujii M, Sandel J, et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol. 2013 [Epub ahead of print] PubMed PMID: 24048504.

28. 28.

    Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013;8:e83481.

29. 29.

    Kawai D, Takaki A, Nakatsuka A, et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology. 2012;56:912–21.

30. 30.

    Cynis H, Kehlen A, Haegele M, et al. Inhibition of glutaminyl cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol. 2013;94:217–25.

31. 31.

    Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol. 2013;58:1218–29.

32. 32.

    Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20:1036–9.

33. 33.

    Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J Med Food. 2007;10:543–7.

34. 34.

    Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res. 2013;46:270–7.

35. 35.

    Trappoliere M, Caligiuri A, Schmid M, et al. Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50:1102–11.

36. 36.

    Sajedianfard J, Behroozi Z, Nazifi S. The effects of a hydroalcoholic extract of silymarin on serum lipids profiles in streptozotocin induced diabetic rats. Comp Clin Pathol. 2014;23:779–84.

37. 37.

    Metwally MAA, El-Gellal AM, El-Sawaisi SM. Effects of silymarin on lipid metabolism in rats. World Appl Sci J. 2009;6:1634–7.